The association of hepatic steatosis and fibrosis with heart failure and mortality

Table 3 Multivariable Cox regression analyses showing the association of advanced liver fibrosis (defined by BARD ≥ 2) with the risk of incident heart failure, hospitalization for heart failure, all-cause mortality and cardiovascular mortality in patients with NAFLD (defined by FLI ≥ 60)

Advanced liver fibrosis	Model 1				Model 2			Model 3			Model 4
Advanced liver fibrosis	Events (n)	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
iHF	3039	1.820	1.698–1.950	< 0.001	1.124	1.045–1.209	0.002	1.136	1.056–1.222	< 0.001	1.116	1.037–1.201	0.003
hHF	1370	2.083	1.868–2.323	< 0.001	1.199	1.069–1.344	0.002	1.219	1.087–1.368	< 0.001	1.201	1.070–1.347	0.002
All-cause mortality	2342	2.104	1.935–2.288	< 0.001	1.235	1.132–1.348	< 0.001	1.248	1.143–1.362	< 0.001	1.240	1.135–1.353	< 0.001
CV mortality	280	2.140	1.677–2.731	< 0.001	1.217	0.943–1.571	0.132	1.262	0.977–1.630	0.075	1.237	0.957–1.598	0.104

CI confidence interval, CV mortality cardiovascular mortality, HR hazard ratio, iHF incident heart failure, hHF incident hospitalized heart failure
Model 1: crude
Model 2: age, sex and body weight
Model 3: model 2 + alcohol drinking, smoking, regular exercise, and income status
Model 4: model 3 + hypertension, dyslipidemia, and estimated glomerular filtration rate

ISSN: 1475-2840